RAPP insider buying and SEC filings, explained
Rapport Therapeutics, Inc. · CIK 2012593
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$22.0M
Insiders who bought
7
Sold (not marked 10b5-1)
$341K
Planned sales (10b5-1)
$46.9M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 28, 2026 | Purchase (code P) | James Healy (Director) bought 969,480 shares indirectly (by entity) at $21.00 ($20.4M), reported as a purchase (code P). Holdings by entity up 51% to 2,815,707 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 30, 2026, 7:32 PM ET |
| Oct 21, 2026 | Planned (10b5-1) | Abraham Ceesay (CEO and Director) sold 2,210 shares at about $29.16 ($64K), marked as a 10b5-1 plan trade. Holdings down <1% to 450,035 shares. | SEC filing Filed Oct 23, 2026, 4:30 PM ET |
| Oct 23, 2026 | Purchase (code P) | Ramiro Sanchez (Director) bought 3,600 shares at about $27.35 ($98K), reported as a purchase (code P). New position of 3,600 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 23, 2026, 4:01 PM ET |
| Oct 22, 2026 | Purchase (code P) | Paul M Silva (Director) bought 3,680 shares indirectly (by trust) at $27.08 ($100K), reported as a purchase (code P). New position of 3,680 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 22, 2026, 4:57 PM ET |
| Oct 22, 2026 | Purchase (code P) | Wendy B. Young (Director) bought 3,789 shares at $26.39 ($100K), reported as a purchase (code P). Holdings up 40% to 13,289 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 22, 2026, 4:56 PM ET |
| Oct 22, 2026 | Purchase (code P) | Steven M. Paul (Director) bought 35,714 shares indirectly (by entity) at about $27.28 ($974K), reported as a purchase (code P). Holdings by entity up 86% to 77,380 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 22, 2026, 4:56 PM ET |
| Oct 22, 2026 | Purchase (code P) | John Maraganore (Director) bought 9,411 shares indirectly (by trust) at about $26.45 ($249K), reported as a purchase (code P). New position of 9,411 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 22, 2026, 4:56 PM ET |
| Oct 21, 2026 | Purchase (code P) | Troy A. Ignelzi (CFO) bought 5,500 shares at $26.10 ($144K), reported as a purchase (code P). Holdings up 55% to 15,500 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 21, 2026, 5:46 PM ET |
| Oct 6–7, 2026 | Planned (10b5-1) | Abraham Ceesay (CEO and Director) sold 4,522 shares between Oct 6 and Oct 7 at about $31.68 ($143K), marked as a 10b5-1 plan trade. Holdings down 1% to 452,245 shares. | SEC filing Filed Oct 8, 2026, 4:07 PM ET |
| Sep 30, 2026 | Planned (10b5-1) | Cheryl Gault (President / COO) sold 10,000 shares at about $33.19 ($332K), marked as a 10b5-1 plan trade. Holdings down 7% to 139,914 shares. | SEC filing Filed Oct 1, 2026, 4:30 PM ET |
| Sep 23, 2026 | Planned (10b5-1) | Abraham Ceesay (CEO and Director) sold 2,210 shares at about $39.17 ($87K), marked as a 10b5-1 plan trade. Holdings down <1% to 456,767 shares. | SEC filing Filed Sep 24, 2026 |
| Sep 8, 2026 | Planned (10b5-1) | Abraham Ceesay (CEO and Director) sold 8,210 shares at about $45.62 ($375K), marked as a 10b5-1 plan trade. Holdings down 2% to 458,977 shares. | SEC filing Filed Sep 9, 2026 |
| Aug 25, 2026 | Planned (10b5-1) | Abraham Ceesay (CEO and Director) sold 18,921 shares at about $49.57 ($938K), marked as a 10b5-1 plan trade. Holdings down 4% to 467,187 shares. | SEC filing Filed Aug 26, 2026 |
| Aug 24–25, 2026 | Planned (10b5-1) | Krishnaswamy Yeleswaram (Chief Development Officer) sold 50,160 shares between Aug 24 and Aug 25 at about $50.47 ($2.5M), marked as a 10b5-1 plan trade. Holdings down 20% to 195,862 shares. | SEC filing Filed Aug 26, 2026 |
| Aug 19, 2026 | Planned (10b5-1) | Krishnaswamy Yeleswaram (Chief Development Officer) sold 404 shares at $49.90 ($20K), marked as a 10b5-1 plan trade. Holdings down <1% to 246,022 shares. | SEC filing Filed Aug 20, 2026 |
| Aug 10–11, 2026 | Planned (10b5-1) | Abraham Ceesay (CEO and Director) sold 51,499 shares between Aug 10 and Aug 11 at about $47.24 ($2.4M), marked as a 10b5-1 plan trade. Holdings down 10% to 486,108 shares. | SEC filing Filed Aug 12, 2026 |
| Jul 27, 2026 | Planned (10b5-1) | Abraham Ceesay (CEO and Director) sold 2,210 shares at about $42.11 ($93K), marked as a 10b5-1 plan trade. Holdings down <1% to 537,607 shares. | SEC filing Filed Jul 29, 2026 |
| Jul 14, 2026 | Planned (10b5-1) | Abraham Ceesay (CEO and Director) sold 8,210 shares at about $40.00 ($328K), marked as a 10b5-1 plan trade. Holdings down 1% to 539,817 shares. | SEC filing Filed Jul 15, 2026 |
| Jun 30, 2026 | Planned (10b5-1) | Cheryl Gault (President / COO) sold 10,000 shares at about $41.58 ($416K), marked as a 10b5-1 plan trade. Holdings down 6% to 149,914 shares. | SEC filing Filed Jul 1, 2026 |
| Jun 29, 2026 | Planned (10b5-1) | Abraham Ceesay (CEO and Director) sold 8,220 shares at about $39.83 ($327K), marked as a 10b5-1 plan trade. Holdings down 1% to 548,027 shares. | SEC filing Filed Jul 1, 2026 |
| May 26, 2026 | Planned (10b5-1) | Third Rock Ventures V, L.P. (10% owner) sold 18,572 shares at about $40.05 ($744K), marked as a 10b5-1 plan trade. Holdings down <1% to 6,280,525 shares. Filed jointly with 5 other reporting owners. | SEC filing Filed May 28, 2026 |
| May 11, 2026 | Planned (10b5-1) | Third Rock Ventures V, L.P. (10% owner) sold 133,618 shares at about $40.24 ($5.4M), marked as a 10b5-1 plan trade. Holdings down 2% to 6,299,097 shares. Filed jointly with 5 other reporting owners. | SEC filing Filed May 13, 2026 |
| May 7–8, 2026 | Planned (10b5-1) | Third Rock Ventures V, L.P. (10% owner) sold 276,513 shares between May 7 and May 8 at about $40.12 ($11.1M), marked as a 10b5-1 plan trade. Holdings down 4% to 6,432,715 shares. Filed jointly with 5 other reporting owners. | SEC filing Filed May 11, 2026 |
| Apr 17, 2026 | Planned (10b5-1) | Third Rock Ventures V, L.P. (10% owner) sold 426,005 shares at about $40.32 ($17.2M), marked as a 10b5-1 plan trade. Holdings down 6% to 6,709,228 shares. Filed jointly with 5 other reporting owners. | SEC filing Filed Apr 21, 2026 |
| Apr 17, 2026 | Planned (10b5-1) | Krishnaswamy Yeleswaram (Chief Development Officer) sold 20,225 shares at about $39.99 ($809K), marked as a 10b5-1 plan trade. Holdings down 8% to 246,426 shares. | SEC filing Filed Apr 21, 2026 |
| Apr 10–14, 2026 | Planned (10b5-1) | Krishnaswamy Yeleswaram (Chief Development Officer) sold 19,865 shares between Apr 10 and Apr 14 at about $35.03 ($696K), marked as a 10b5-1 plan trade. Holdings down 7% to 266,651 shares. | SEC filing Filed Apr 14, 2026 |
| Apr 8, 2026 | Planned (10b5-1) | Krishnaswamy Yeleswaram (Chief Development Officer) sold 360 shares at $34.90 ($13K), marked as a 10b5-1 plan trade. Holdings down <1% to 286,516 shares. | SEC filing Filed Apr 9, 2026 |
| Mar 30, 2026 | Planned (10b5-1) | Cheryl Gault (President / COO) sold 10,000 shares at about $28.18 ($282K), marked as a 10b5-1 plan trade. Holdings down 6% to 159,914 shares. | SEC filing Filed Mar 31, 2026 |
| Mar 25, 2026 | Planned (10b5-1) | Krishnaswamy Yeleswaram (Chief Development Officer) sold 10,115 shares at about $29.99 ($303K), marked as a 10b5-1 plan trade. Holdings down 3% to 286,876 shares. | SEC filing Filed Mar 26, 2026 |
| Mar 5, 2026 | Sale | Cheryl Gault (President / COO) sold 2,014 shares at about $28.93 ($58K). Holdings down 1% to 169,914 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 9, 2026 |
| Feb 18, 2026 | Planned (10b5-1) | Abraham Ceesay (CEO and Director) sold 10,916 shares directly and indirectly (by trust) at about $29.35 ($320K), marked as a 10b5-1 plan trade. Direct holdings down 1% to 556,247 shares. | SEC filing Filed Feb 19, 2026 |
| Feb 17, 2026 | Planned (10b5-1) | David Bredt (Chief Scientific Officer) sold 8,500 shares at about $29.02 ($247K), marked as a 10b5-1 plan trade. Holdings down 2% to 387,075 shares. | SEC filing Filed Feb 19, 2026 |
| Jan 20, 2026 | Planned (10b5-1) | Abraham Ceesay (CEO and Director) sold 10,916 shares directly and indirectly (by trust) at about $26.12 ($285K), marked as a 10b5-1 plan trade. Direct holdings down 1% to 562,080 shares. | SEC filing Filed Jan 22, 2026 |
| Jan 15, 2026 | Planned (10b5-1) | David Bredt (Chief Scientific Officer) sold 8,500 shares at about $26.84 ($228K), marked as a 10b5-1 plan trade. Holdings down 2% to 395,575 shares. | SEC filing Filed Jan 16, 2026 |
| Dec 31, 2025 | Sale | David Bredt (Chief Scientific Officer) sold 6,567 shares at about $30.05 ($197K). Holdings down 2% to 404,075 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 5, 2026 |
| Dec 31, 2025 | Sale | Krishnaswamy Yeleswaram (Chief Development Officer) sold 2,840 shares at $30.05 ($85K). Holdings down 1% to 296,991 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 5, 2026 |
| Dec 17, 2025 | Planned (10b5-1) | Abraham Ceesay (CEO and Director) sold 10,916 shares directly and indirectly (by trust) at about $29.64 ($324K), marked as a 10b5-1 plan trade. Direct holdings down 1% to 567,913 shares. | SEC filing Filed Dec 18, 2025 |
| Dec 15, 2025 | Planned (10b5-1) | David Bredt (Chief Scientific Officer) sold 8,500 shares at about $30.02 ($255K), marked as a 10b5-1 plan trade. Holdings down 2% to 392,642 shares. | SEC filing Filed Dec 16, 2025 |
| Nov 26, 2025 | Planned (10b5-1) | Cheryl Gault (President / COO) sold 5,000 shares at about $30.10 ($151K), marked as a 10b5-1 plan trade. Holdings down 3% to 171,928 shares. | SEC filing Filed Dec 1, 2025 |
| Nov 17, 2025 | Planned (10b5-1) | Abraham Ceesay (CEO and Director) sold 10,916 shares directly and indirectly (by trust) at about $25.20 ($275K), marked as a 10b5-1 plan trade. Direct holdings down 1% to 573,746 shares. | SEC filing Filed Nov 18, 2025 |
| Nov 17, 2025 | Planned (10b5-1) | David Bredt (Chief Scientific Officer) sold 8,500 shares at about $25.19 ($214K), marked as a 10b5-1 plan trade. Holdings down 2% to 401,142 shares. | SEC filing Filed Nov 18, 2025 |
18 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
7 insiders bought in 30 days
$22.0M in purchases since Oct 21, 2026 · Purchases traded Oct 21, 2026 to Oct 28, 2026 · Active
| Insider | Value | Traded | Source |
|---|---|---|---|
| Troy A. Ignelzi (CFO) | $144K | Oct 21, 2026 | SEC filing |
| John Maraganore (Director) | $249K | Oct 22, 2026 | SEC filing |
| Steven M. Paul (Director) | $974K | Oct 22, 2026 | SEC filing |
| Wendy B. Young (Director) | $100K | Oct 22, 2026 | SEC filing |
| Paul M Silva (Director) | $100K | Oct 22, 2026 | SEC filing |
| Ramiro Sanchez (Director) | $98K | Oct 23, 2026 | SEC filing |
| James Healy (Director) | $20.4M | Oct 28, 2026 | SEC filing |
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow RAPP in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.